vs
Side-by-side financial comparison of FRANKLIN STREET PROPERTIES CORP (FSP) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $26.0M, roughly 1.5× FRANKLIN STREET PROPERTIES CORP). FRANKLIN STREET PROPERTIES CORP runs the higher net margin — -28.1% vs -161.8%, a 133.7% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -8.2%). FRANKLIN STREET PROPERTIES CORP produced more free cash flow last quarter ($-12.7M vs $-71.3M).
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
FSP vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0M | $38.3M |
| Net Profit | $-7.3M | $-61.9M |
| Gross Margin | 59.4% | 99.0% |
| Operating Margin | -27.9% | -169.0% |
| Net Margin | -28.1% | -161.8% |
| Revenue YoY | -8.2% | 407.0% |
| Net Profit YoY | 14.1% | -4.7% |
| EPS (diluted) | $-0.06 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0M | $38.3M | ||
| Q3 25 | $27.3M | $32.1M | ||
| Q2 25 | $26.7M | $26.4M | ||
| Q1 25 | $27.1M | $16.5M | ||
| Q4 24 | $28.4M | $7.6M | ||
| Q3 24 | $29.7M | $6.1M | ||
| Q2 24 | $30.8M | — | ||
| Q1 24 | $31.2M | — |
| Q4 25 | $-7.3M | $-61.9M | ||
| Q3 25 | $-8.3M | $-67.3M | ||
| Q2 25 | $-7.9M | $-92.6M | ||
| Q1 25 | $-21.4M | $-129.6M | ||
| Q4 24 | $-8.5M | $-59.2M | ||
| Q3 24 | $-15.6M | $-85.7M | ||
| Q2 24 | $-21.0M | — | ||
| Q1 24 | $-7.6M | — |
| Q4 25 | 59.4% | 99.0% | ||
| Q3 25 | 60.9% | 99.4% | ||
| Q2 25 | 59.9% | 99.5% | ||
| Q1 25 | 62.8% | 99.6% | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 61.0% | — | ||
| Q2 24 | 64.2% | — | ||
| Q1 24 | 64.7% | — |
| Q4 25 | -27.9% | -169.0% | ||
| Q3 25 | -30.5% | -173.5% | ||
| Q2 25 | -29.2% | -269.8% | ||
| Q1 25 | -78.9% | -390.1% | ||
| Q4 24 | -29.9% | -919.0% | ||
| Q3 24 | -52.4% | -1314.3% | ||
| Q2 24 | -68.0% | — | ||
| Q1 24 | -24.0% | — |
| Q4 25 | -28.1% | -161.8% | ||
| Q3 25 | -30.5% | -209.8% | ||
| Q2 25 | -29.5% | -350.3% | ||
| Q1 25 | -79.1% | -784.9% | ||
| Q4 24 | -30.0% | -783.4% | ||
| Q3 24 | -52.6% | -1404.0% | ||
| Q2 24 | -68.2% | — | ||
| Q1 24 | -24.2% | — |
| Q4 25 | $-0.06 | $-0.06 | ||
| Q3 25 | $-0.08 | $-0.07 | ||
| Q2 25 | $-0.08 | $-0.10 | ||
| Q1 25 | $-0.21 | $-0.15 | ||
| Q4 24 | $-0.09 | $-0.08 | ||
| Q3 24 | $-0.15 | $-0.14 | ||
| Q2 24 | $-0.20 | — | ||
| Q1 24 | $-0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $30.6M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $607.0M | $-500.5M |
| Total Assets | $892.9M | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.6M | $242.8M | ||
| Q3 25 | $31.4M | $257.8M | ||
| Q2 25 | $29.4M | $153.7M | ||
| Q1 25 | $30.2M | $61.6M | ||
| Q4 24 | $41.1M | $149.8M | ||
| Q3 24 | $40.9M | $130.4M | ||
| Q2 24 | $30.2M | — | ||
| Q1 24 | $34.2M | — |
| Q4 25 | $607.0M | $-500.5M | ||
| Q3 25 | $615.3M | $-524.3M | ||
| Q2 25 | $624.7M | $-570.7M | ||
| Q1 25 | $633.4M | $-591.4M | ||
| Q4 24 | $655.9M | $-489.1M | ||
| Q3 24 | $665.4M | $-745.1M | ||
| Q2 24 | $682.1M | — | ||
| Q1 24 | $703.9M | — |
| Q4 25 | $892.9M | $501.9M | ||
| Q3 25 | $901.0M | $519.0M | ||
| Q2 25 | $903.2M | $402.1M | ||
| Q1 25 | $916.4M | $303.8M | ||
| Q4 24 | $946.9M | $382.9M | ||
| Q3 24 | $981.5M | $364.6M | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.8M | $-70.4M |
| Free Cash FlowOCF − Capex | $-12.7M | $-71.3M |
| FCF MarginFCF / Revenue | -48.6% | -186.2% |
| Capex IntensityCapex / Revenue | 63.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-25.3M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.8M | $-70.4M | ||
| Q3 25 | $8.3M | $-68.9M | ||
| Q2 25 | $-2.9M | $-79.7M | ||
| Q1 25 | $-5.5M | $-85.9M | ||
| Q4 24 | $9.0M | $-85.1M | ||
| Q3 24 | $14.5M | $-98.8M | ||
| Q2 24 | $-648.0K | — | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | $-12.7M | $-71.3M | ||
| Q3 25 | $3.0M | $-69.6M | ||
| Q2 25 | $-5.7M | $-80.8M | ||
| Q1 25 | $-9.9M | $-87.0M | ||
| Q4 24 | $-16.2M | $-87.3M | ||
| Q3 24 | $8.6M | $-101.6M | ||
| Q2 24 | $-5.1M | — | ||
| Q1 24 | $-15.8M | — |
| Q4 25 | -48.6% | -186.2% | ||
| Q3 25 | 11.0% | -217.2% | ||
| Q2 25 | -21.5% | -305.9% | ||
| Q1 25 | -36.7% | -526.9% | ||
| Q4 24 | -57.2% | -1155.4% | ||
| Q3 24 | 29.1% | -1663.2% | ||
| Q2 24 | -16.7% | — | ||
| Q1 24 | -50.8% | — |
| Q4 25 | 63.0% | 2.4% | ||
| Q3 25 | 19.4% | 2.3% | ||
| Q2 25 | 10.7% | 4.1% | ||
| Q1 25 | 16.4% | 6.8% | ||
| Q4 24 | 88.9% | 28.0% | ||
| Q3 24 | 19.6% | 45.7% | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 28.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
